Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANJIT R NAIR

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1407055221
CMS profile
1115162
Location
N.RICHLAND HILLS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$30,526.90

240 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 240 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANJIT R NAIR

NPI 1407055221 · CMS profile ID 1115162

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

N.RICHLAND HILLS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 240 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407055221?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANJIT R NAIR, NPI 1407055221, CMS profile ID 1115162. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 240 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407055221?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RANJIT R NAIR, NPI 1407055221, CMS profile ID 1115162. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 240 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407055221?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RANJIT R NAIR, NPI 1407055221, CMS profile ID 1115162, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 240 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1407055221?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

240 matching records · $30,526.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 240 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 240.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insmed, Inc. $12.1406/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186310715 CMS
AstraZeneca Pharmaceuticals LP $15.1506/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206175758 CMS
Insmed, Inc. $12.9806/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186308048 CMS
Inspire Medical Systems, Inc. $34.2606/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251492812 CMS
Verona Pharma, Inc. $3.1306/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233771021 CMS
Avadel CNS Pharmaceuticals, LLC $3.1406/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208539062 CMS
Insmed, Inc. $13.4706/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186310767 CMS
Regeneron Healthcare Solutions, Inc. $27.0606/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212997109 CMS
Actelion Pharmaceuticals US, Inc. $32.8806/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174304618 CMS
GlaxoSmithKline, LLC. $7.0806/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190619006 CMS
GENZYME CORPORATION $13.5105/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233401410 CMS
GlaxoSmithKline, LLC. $14.2205/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190415167 CMS
GlaxoSmithKline, LLC. $9.0805/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190426364 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.5805/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223829692 CMS
Amgen Inc. $10.5305/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227130139 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,870.0005/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1222984189 CMS
GlaxoSmithKline, LLC. $23.2005/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190503209 CMS
GlaxoSmithKline, LLC. $17.6805/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191482253 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,700.0005/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1222984193 CMS
GlaxoSmithKline, LLC. $21.3505/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191093474 CMS
JAZZ PHARMACEUTICALS INC. $28.4205/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234324427 CMS
Viatris Specialty LLC $116.1605/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238484507 CMS
Viatris Specialty LLC $2,136.0005/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238484511 CMS
Viatris Specialty LLC $4.7005/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238505325 CMS
Inspire Medical Systems, Inc. $16.4805/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251492810 CMS
Verona Pharma, Inc. $9.3905/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233771053 CMS
Amgen Inc. $16.8505/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228662239 CMS
Insmed, Inc. $10.5205/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186263631 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.4604/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222984181 CMS
Inspire Medical Systems, Inc. $26.8804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251492808 CMS
Regeneron Pharmaceuticals, Inc. $147.1304/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213241451 CMS
Actelion Pharmaceuticals US, Inc. $29.5904/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174304594 CMS
HARMONY BIOSCIENCES LLC $15.0004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222401730 CMS
GlaxoSmithKline, LLC. $12.5204/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190909940 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $123.1504/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222984191 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $821.2804/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1222984197 CMS
Grifols USA, LLC $2.7504/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249542270 CMS
Viatris Specialty LLC $22.9804/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238504353 CMS
GlaxoSmithKline, LLC. $12.5204/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190766019 CMS
GENZYME CORPORATION $11.9604/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233401390 CMS
Inspire Medical Systems, Inc. $2.9104/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251492806 CMS
Avadel CNS Pharmaceuticals, LLC $19.6804/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208539060 CMS
Viatris Specialty LLC $11.6804/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238502745 CMS
Edwards Lifesciences Corporation $148.3204/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225269701 CMS
GlaxoSmithKline, LLC. $15.9804/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190764635 CMS
AstraZeneca Pharmaceuticals LP $20.7204/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207273189 CMS
GlaxoSmithKline, LLC. $6.8004/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191323918 CMS
JAZZ PHARMACEUTICALS INC. $99.9903/28/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1234308976 CMS
Amgen Inc. $20.2303/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228662231 CMS
Fisher & Paykel Healthcare Inc $29.5203/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244152063 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,630.84 120
PY2020 $5,084.48 36
PY2021 $5,629.72 57
PY2022 $21,575.50 125
PY2023 $24,254.26 155
PY2024 $26,989.51 191
PY2025 $30,526.90 240

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $285,042.70 11
PY2024 Principal investigator $181,095.12 34
PY2023 Principal investigator $164,951.60 1
PY2022 Principal investigator $149,799.71 2
PY2021 Principal investigator $244,864.30 4
PY2020 Principal investigator $7,242.10 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $496.14 11/19/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262599
Principal investigator 1 AstraZeneca Pharmaceuticals LP $263.00 11/10/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185550195
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.05 06/11/2025 Non-covered Recipient Entity
The Lung and Sleep Research Institute of North Texas
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,535.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,500.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $974.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188619
Principal investigator 1 AstraZeneca Pharmaceuticals LP $264,331.19 03/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185550193
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,177.32 02/10/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CLINICAL CANCER PREVENTION
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185550197